Allogene Therapeutics
Update in progressALLO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Allogene Therapeutics is a clinical-stage immuno-oncology company that develops and commercializes genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. Its pipeline uses protein engineering, gene editing, gene insertion, and advanced manufacturing. Key programs include cema-cel (CD19) for large B-cell lymphoma, ALLO-316 (CD70) for RCC, and ALLO-329 (CD19/CD70) for autoimmune diseases such as SLE, IIM, and SSc. Founded 2017, South San Francisco.
Company score
- Sentiment
- -0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.42
- Governance
- -0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Zachary J. Roberts M.D., Ph.D.
- Founded2017
- Employees150
- Websiteallogene.com
Identifiers
- ISINUS0197701065
- FIGIBBG00KHRRDX3
- CUSIP019770106
- CIK0001737287